You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康方生物(09926.HK)旗下宮頸癌藥物臨床試驗達無進展生存期主要終點
阿思達克 11-23 09:17
康方生物(09926.HK)公布,其自主研發的全球首創開坦尼(卡度尼利,PD-1/CTLA-4)雙特異性抗體聯合含鉑化療聯合或不聯合貝伐珠單抗一線治療持續、復發或轉移性宮頸癌患者的III期臨床試驗(AK104-303),在由獨立數據監察委員會(IDMC)進行的期中分析,達到無進展生存期(PFS)主要研究終點。 截止本次分析,該試驗另一研究終點總生存期(OS)尚未達到事件數,未作正式統計分析,但已顯示改善趨勢,該試驗將按計劃繼續進行。另外,卡度尼利的安全性特徵與既往發表的相關臨床研究結果一致,無新的安全性信號。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account